My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sol-Gel Technologies Ltd. - Ordinary Shares (NQ:SLGL)

40.51 -1.25 (-2.99%)
Streaming Delayed Price Updated: 3:39 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sol-Gel Technologies Ltd. - Ordinary Shares

< Previous 1 2 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Sol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays Pessimistic
The company’s diluted loss per share came in at $3.2, exceeding an estimated loss of $1.2. 
Via Stocktwits
Topics Government
US Stocks Gain, Nasdaq Surges Over 100 Points
 
Via Benzinga
Why Carbon Revolution Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Sol-Gel Technologies: Q4 Earnings Insights
 
Via Benzinga
Recap: Sol-Gel Technologies Q3 Earnings
 
Via Benzinga
Expert Ratings for Sol-Gel Technologies
 
Via Benzinga
Sol-Gel Technologies: Q1 Earnings Insights
Sol-Gel Technologies (NASDAQ:SLGL) reported its Q1 earnings results on Friday, May 13, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
SLGL Stock Earnings: Sol-Gel Technologies Beats EPS, Beats Revenue for Q2 2024
SLGL stock results show that Sol-Gel Technologies beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
SLGL Stock Earnings: Sol-Gel Technologies Misses EPS, Misses Revenue for Q1 2024
SLGL stock results show that Sol-Gel Technologies missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Week in Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
In the headline deal, Takeda acquires global rights from AC Immune of Switzerland for $100 million upfront and up to $2.1B in milestones. 
Via Talk Markets
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 369 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 112 companies set new 52-week lows. 
Via Benzinga
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) Making Surprising Moves in Wednesday Session
Via Investor Brand Network
7 Biotech Stocks That Could Be the Next Big Thing
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 386 stocks made new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
The Top 7 Penny Stocks to Invest in for the Long-Term
Although penny stocks represent extremely high risks, a select few ideas could make for enticing long-term propositions. 
Via InvestorPlace
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at... 
Via Benzinga
Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday. 
Via Benzinga
What Does Sunshine Biopharma's Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market?
The generic drug market has been growing since 1984 when the Hatch-Waxman Act encouraged manufacturing generics and developed a framework to regulate them. 
Via Benzinga
Nasdaq Turns Higher; Applied Genetic Technologies Shares Surge
U.S. stocks traded mostly higher midway through trading, with the Dow Jones surging more than 300 points on Monday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022
Upgrades 
Via Benzinga
Why Is Allena Pharmaceuticals Jumping By 207%? 45 Stocks Moving In Wednesday's Mid-Day Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 207% to $0.3650 after the company announced it has terminated its previously announced at-the-market offering. 
Via Benzinga
Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday
Gainers United Maritime Corporation (NASDAQ: USEA) shares climbed 175.9% to close at $6.07 on Friday. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering... 
Via Benzinga
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &... 
Via Benzinga
Citigroup, Bank of America And 48 Stocks Moving In Friday's Mid-Day Session
Gainers United Maritime Corporation (NASDAQ: USEA) shares jumped 180.9% to $6.19. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering on Wednesday. 
Via Benzinga
Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris
The FDA has approved Sol-Gel Technologies Ltd's (NASDAQ: SLGL) first proprietary drug product, Twyneo (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated... 
Via Benzinga
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter. • Vericel (NASDAQ:VCEL) is expected to... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.